Coya Therapeutics Details Upcoming Board Transition, Names Mark H. Pavao as Independent Director Coya Therapeutics, Inc., a clinical-stage biotechnology company focused on developing innovative biologic therapies designed to enhance regulatory…
Curve Biosciences Announces Appointment of Dr. Amit Singal as Chief Medical Officer Curve Biosciences, a company focused on advancing innovative approaches to whole-body intelligence in healthcare, has announced the appointment…
PureTech Reports Publication of Phase 2b ELEVATE IPF Trial Results in Leading Respiratory Medicine Journal PureTech Health plc, a clinical-stage biotherapeutics company focused on translating cutting-edge science into transformative therapies,…
Glycomine Announces Completion of Enrollment in Global Phase 2b POLAR Study Evaluating GLM101 for PMM2-CDG Glycomine, Inc. has announced the successful completion of patient enrollment in its Phase 2b POLAR…
Tenpoint Therapeutics and PHIL Collaborate to Introduce YUVEZZI™ Direct-to-Patient Cash Program, Improving Access and Affordability for Presbyopia Care Tenpoint Therapeutics, a company focused on advancing innovative treatments in eye care,…
PharmaEssentia Announces Investment Agreement to Build New Manufacturing Facility in Puerto Rico PharmaEssentia Corporation, a global biopharmaceutical company headquartered in Taiwan, has taken a significant step in expanding its international…
Feinstein Institutes Honors Drs. Michel Sadelain and Carl H. June with the 2026 Ross Prize in Molecular Medicine The Feinstein Institutes for Medical Research has announced that two pioneers of…
Target RWE Enhances Leadership Team with Key Appointments Across Delivery, Finance, and Commercial Functions Target RWE, a company focused on advancing modern approaches to clinical evidence generation, has announced a…
SV Health Investors Completes Acquisition of EpiVax SV Health Investors has announced the acquisition of EpiVax, Inc., a well-established contract research organization (CRO) specializing in immunogenicity risk assessment for pharmaceutical…
Vedanta Biosciences Confirms Phase 3 RESTORATiVE303 Study of VE303 Will Proceed as Planned Following Interim Analysis Vedanta Biosciences, a late clinical-stage company focused on developing microbiome-based oral therapies for gastrointestinal…
INLEXZO™ (gemcitabine intravesical system) Receives Permanent Billing Code to Enhance Access for Select Bladder Cancer Patients Johnson & Johnson has announced a key reimbursement milestone for its bladder cancer therapy…
FDA Clears Lilly’s Foundayo™ (orforglipron), the First GLP-1 Weight Loss Pill with No Food or Timing Restrictions Eli Lilly and Company has announced a major milestone in the treatment of…